HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Clinical trials for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Simple blood test could predict breast cancer return
Knowledge-focused Recruiting nowThis study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC